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Abstract
Background: A previous study has documented the reliability and validity of the Treatment Satisfaction with
Medicines Questionnaire (SATMED-Q) in exploring patient satisfaction with medicines for chronic health conditions
in routine medical practice, but the minimally important difference (MID) of this tool is as yet unknown. The
objective of this research was to estimate the MID for the SATMED-Q total score and six constituent domains.
Methods: The sample of patients (456 subjects, mean age 59 years, 53% male) used for testing psychometric
properties was also used to assess MID. Item #14 of the Treatment Satisfaction Questionnaire for Medication
(TSQM) was used as an anchor reference since it directly explores satisfaction with medicine on a 7-point ordinal
scale (from extremely satisfied to extremely dissatisfied, with a neutral category). Patients were classified into four
categories according to responses to this item (extremely satisfied/dissatisfied, very satisfied/dissatisfied, satisfied/
dissatisfied, neither satisfied nor dissatisfied (neutral), and calculations were made for the total score and each
domain of the SATMED-Q using standardised scores. The mean absolute differences in total score (and domains)
between the neutral category and the satisfied/dissatisfied category were considered to be the MID. Effect sizes
(ES) were also computed.
Results: The MID for the total score was 13.4 (ES = 0.91), while the domain values ranged from 10.3 (medical care
domain, ES = 0.43) to 20.6 (impact on daily living, ES = 0.85). Mean differences in satisfaction (as measured by the
total SATMED-Q score and domain scores) using the levels of satisfaction established by item #14 were significantly
different, with F values ranging from 12.2 to 88.8 (p < 0.001 in all cases).
Conclusion: The SATMED-Q was demonstrated to be responsive to different levels of patient satisfaction with
therapy in chronically ill subjects. The MID obtained was 13.4 points for the overall normalised scoring scale, and
between 10.3 and 20.6 points for domains.
Keywords: meaningful difference, minimally important difference, SATMED-Q, satisfaction, chronic health condi-
tions, medicines
Background
In recent years, there has been a series of health-related
changes in industrialised countries, directly resulting in
the introduction of new concepts or factors to be con-
sidered when evaluating health care. One of the most
important of these changes is the spectacular increase in
life expectancy, with the consequent aging of the
population. This phenomenon is largely attributable to
advances in medicine, and has resulted in changes in
mortality and morbidity rates. In the treatment of
chronic diseases, the traditional measures of morbidity
and mortality, together with other biomedical para-
meters, only partially evaluate the effectiveness of drugs
and other medical interventions which, while prolonging
patient life, do not offer a cure. When the treatments
administered do not modify survival rates, when there is
not a significant difference between them, or when the
treatments and other medical interventions cause
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arises to evaluate effectiveness in other terms [1]. Health
Outcomes Research, a relatively new discipline, focuses
among other things on the measurement of disease and
treatment impact upon patient-perceived health [2,3].
Patient satisfaction is related to all aspects of health-
care that are of relevance to health. The concept
includes satisfaction with both the medical care received
and with the specific treatments prescribed by clini-
cians [4,5]. Patient satisfaction can be considered a pyra-
mid where satisfaction with healthcare is located at the
base. This covers all aspects of the care received and
includes patient satisfaction with access to medical care,
physician behaviour and technical competence, the ser-
vices provided, the costs, and the treatment selected.
Overall treatment satisfaction lies at an intermediate
level of the pyramid and includes all related aspects:
effectiveness, convenience, undesirable effects, follow-up,
etc. Lastly, we find satisfaction with the medication
received - this being the patient’s evaluation of the pro-
cess of administering the medication - and the asso-
ciated results at the top of the pyramid [5]. There would
seem to be a relationship between satisfaction with med-
ication and medical treatment and patient adherence or
compliance with treatment. It is therefore a quality indi-
cator that can be used to improve healthcare and one
that also affects patient preferences [4,6-11]. In addition,
knowledge of the degree of satisfaction with treatment
may make it easier to predict treatment compliance and
help clinicians take health-related decisions. Therefore,
this parameter may be a useful indicator to measure in
daily practice and biomedical research [12].
The Treatment Satisfaction with Medicines Question-
naire (SATMED-Q) is a brief, feasible and easy to self-
administer multidimensional generic questionnaire with
good metric properties of reliability and validity [13]. It
was designed for use in patients with any chronic dis-
ease treated with medicines. The questionnaire was
developed assuming the Classical Test Theory frame-
work [14-16], whose properties have been proven to be
valid and reliable for chronic health conditions in rou-
tine medical practice. Minimal important difference
(MID) is a phrase with instant appeal in a field strug-
gling to interpret health-related quality of life and other
patient-reported outcomes. It is defined as “the smallest
difference in score in the domain of interest which
patients perceive as beneficial and which would man-
date, in the absence of troublesome side effects and
excessive cost, a change in the patient’s manage-
ment" [17]. The terminology can be confusing, with sev-
eral terms differing only slightly in definition (e.g.
minimal clinically important difference, clinically impor-
tant difference, minimally detectable difference, subjec-
tively significant difference). Four methods are
commonly used to estimate MIDs: patient rating of
change (global transition items); clinical anchors; stan-
dard error (SE) of measurement; and effect size [17,18].
This is important since the MID allows clinicians to bet-
ter interpret their medical interventions and possible
changes in a patient’s well-being after treatment with
medicines [18]. However, the minimally important dif-
ference (MID) of the instrument is as yet unknown.
Thus, the aim of this research was to ascertain the MID
for the SATMED-Q ? for both its total score and
domains.
Methods
Design of the study and sample
A multi-centre, cross-sectional, observational study was
conducted under routine clinical practice conditions in
terms of disease treatment. The study protocol was
approved by the Universidad Autónoma de Madrid
Independent Ethics Committee (CEI 13-226 on 13 July
2005). The sample of patients analysed for testing the
cross-sectional properties of the instrument was also
used to calculate MID and effect sizes. The sample
design and sampling procedure have been documented
elsewhere [13], and sample characteristics are shown in
Table 1. In brief, this sample consisted of patients diag-
nosed with different diseases prevalent in our clinical
setting, such as type 2 diabetes mellitus, hypertension,
osteoarthritis, benign prostatic hyperplasia (BPH),
chronic obstructive pulmonary disease (COPD)/asthma,
depression, and migraine. For patient recruitment, the
researchers carried out probabilistic sampling at six
health centres in the Madrid region and a tertiary hospi-
tal in the city of Madrid. Patients were selected from
those visiting the centre who met the following study
inclusion criteria: male or female outpatients over 18
years of age; diagnosed with one of the aforementioned
diseases or health conditions; a duration of treatment
for the disorder greater than 2 months at time of enrol-
ment; ability to understand and answer the Spanish ver-
sions of the study health questionnaires; and willingness
to sign the informed consent form.
The size of the sample was determined based on the
Rummel’s criterion [19], whereby the ratio of subjects to
variables should be no less than 4:1. However, the sample
size was increased to allow statistical comparisons between
meaningful groups related to the validation study. Thus, to
prevent missed data, we decided to select a minimum of
50 patients (25 males and 25 females) corresponding to
each of the 7 disease conditions considered in the study,
representing a minimum of 350 patients in total. The vali-
dation sample finally comprised 456 patients. Table 1
shows the number of cases sampled per stratum, in addi-
tion to the mean age, mean body mass index (BMI), and
the distributions for ethnicity and educational level.
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In addition to the SATMED-Q, the Spanish version of
the TSQM (Treatment Satisfaction Questionnaire for
Medication) [20] was used to test concurrent validity of
the SATMED-Q, and item #14 of the scale in particular
was also used as an anchor reference. The TSQM is a
14-item Likert-type self-administered instrument with 4
subscales or domains: satisfaction with side-effects,
effectiveness, convenience of use and overall satisfaction,
which account for 77% of available variance. Moreover,
it is possible to calculate a total composite score sum-
marising all domains.
As mentioned above, the SATMED-Q is a brief, feasi-
ble and easy to self-administer multidimensional generic
questionnaire comprising 17 Likert-type items [13]. It
has been designed for use in patients with any chronic
disease taking any type of prolonged pharmacological
treatment. The instrument is made up of six domains or
dimensions exploring satisfaction with drug efficacy,
side-effects, convenience of use, medical care, impact on
activities of daily living and general satisfaction, which
account for 80.8% of available variance. It also provides
an overall score for satisfaction with drug treatment by
summing up all ?domains.
Both scales were self-administered in the waiting room
during the same office visit. Item #14 of the TSQM
(Taking all things into account, how satisfied or
dissatisfied are you with this medication?) was used as
an anchor reference since it directly explores satisfaction
with drug treatment on a seven-category ordinal scale,
from extremely satisfied to extremely dissatisfied, with a
neutral category in the middle.
Calculation of the Minimally Important Difference (MID)
and statistical procedures
A triangulation approach was followed to estimate the
M I Do ft h eS A T M E D - Q :a na nchor-based method and
three distribution-based methods [21]. The mean abso-
lute differences in total score between the neutral cate-
gory response and the contiguous satisfied/dissatisfied
response categories (both merged into a single response
group) for TSQM item #14 were considered a valid esti-
mate of MID values for the overall scoring of the
SATMED-Q instrument using an anchor-based
approach. A similar procedure was followed to obtain
MID estimates for each individual SATMED-Q dimen-
sion. Patients were first classified into four categories
according to responses to item #14 in order to quantify
the magnitude of the patient’s perceived distance from
the neutral response category: extremely satisfied/dissa-
tisfied (merged), very satisfied/dissatisfied (merged),
satisfied/dissatisfied (merged), neither satisfied nor dissa-
tisfied (single neutral category). Average score and stan-
dard deviation were computed for each response group
Table 1 Demographic characteristics of patients included in the study (n = 456)
Age: mean (SD) 62.07 (13.61)
Gender, male: n (%) 229 (50.2%)
BMI (kg/m2): mean (SD) 27.77 (4.71)
Race
Caucasian 443 (97.2%)
African 6 (1.3%)
Other 7 (1.5%)
Education
No secondary school 247 (54.2%)
Completed secondary school 106 (23.2%)
Vocational training diploma 42 (9.2%)
University graduate 54 (11.8%)
Unknown 7 (1.5%)
Male Female
No. of patients by disease* < 65 years ≥ 65 years < 65 years ≥ 65 years
Diabetes 17 (3.7%) 16 (3.5%) 7 (3.7%) 21 (4.6%)
Hypertension 21 (4.6%) 27 (5.9%) 27 (5.9%) 27 (5.9%)
Osteoarthritis 17 (3.7%) 18 (3.9%) 17 (3.7%) 18 (3.9%)
BPH 16 (3.5%) 24 (5.3%) - -
COPD/asthma 13 (2.9%) 16 (3.5%) 15 (3.5%) 15 (3.5%)
Depression 15 (3.3%) 14 (3.1%) 24 (5.3%) 17 (3.7%)
Migraine 10 (2.2%) 5 (1.1%) 19 (4.2%) 9 (2.0%)
Total 109 (23.9%) 120 (26.4%) 119 (26.2%) 107 (23.5%)
BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; BPH = Benign Prostatic Hyperplasia. *Age was missing for one patient.
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SATMED-Q expressed as a 0-100 normalised or stan-
dardised score. This methodological approach has pre-
viously been used by other researchers [17,21-26].
Although our main concern was with the minimal per-
ceived difference, differences for all response groups
with respect to the neutral category were also computed
since we found step-scaled differences to be informative,
and we did not know in advance if perceived differences
could be monotonically distributed by corresponding
distance levels.
Difference between neutral and satisfied/dissatisfied
was considered to be the MID value, while differences
between neutral and the other two categories were clas-
sified as medium and large differences, respectively.
Effect size (ES) was also computed as a distribution-
based method along with the standard error of measure-
ment (SEM) and one-half of a standard deviation (SD)
to support congruence of the main method for MID cal-
culation, as other investigators have done in the field of
patient satisfaction with medical care [25,26]. The ES
was computed according to the Kazis et al. method [27],
dividing the SATMED-Q mean response difference for
the minimum change level determined using TSQM
item #14 by the pooled standard deviation of the whole
sample for a given domain or the total score. Interpreta-
tion of the effect size was based on the established cri-
terion which considers an effect size of 0.20 - <0.50 as
small; a size of ≥ 0.50 and < 0.80 as moderate; and a
size of ≥ 0.80 as large [27]. The SEM was obtained by
multiplying the baseline standard deviation of the scale,
or domain, by the square root of one minus its reliabil-
ity coefficient [28]. Scale reliability was estimated using
Cronbach’s alpha coefficient [29].
In addition to the above analyses, exploratory descrip-
tive statistics were performed using measures of central
tendency and dispersion, and the Kolmogorov-Smirnov
test was applied to test for a normal distribution of
scores. An ANOVA and the Levene test for homogene-
ity of variance testing were used to check that differ-
ences in SATMED-Q scores could be interpretable
when the sample was stratified by satisfaction levels
using TSQM item #14.
A bootstrap re-sampling method was used to obtain
confidence interval estimates for the MID and medium
and large differences. A total of 1000 random samples
with replacement were extracted and mean differences
from the reference category were computed. The per-
centile method was used to obtain 95% confidence lim-
its. Bootstrap estimates may also be considered a more
valid measure of general population values when clinical
samples are used and community samples are not gath-
ered, given that they increase the likelihood of identify-
ing outlier subjects to be re-sampled.
Since both TSQM and SATMED-Q are patient
reported outcomes (PRO), it could be argued that there
might be a lack of external validity in the assessment of
minimally important differences. For this reason, differ-
ences in the SATMED-Q effectiveness dimension were
compared with treatment effectiveness groups as
assessed by the clinician on a 4-point Likert-type scale
(poor, acceptable, good, and excellent). Mean difference
values are reported as a reference.
All tests were two-sided and a type I error (a) < 0.05
was assumed to be significant. A Bonferroni adjustment
was applied for multiple comparisons. All analyses were
performed using SPSS version 18.0 statistical software.
Results
The cross-sectional phase of the study for the develop-
ment of the SATMED-Q enrolled 456 subjects with dif-
ferent diseases or health conditions (Table 1). The item
non-response rate was very low: 96.7% of the patients
answered all questions on the questionnaire. The aver-
age response time was 4.71 minutes (SD = 4.65). The
median completion time was 4 minutes. The overall
composite scores exhibited a negative skewed distribu-
tion, with a mean of 75.03 and a standard deviation of
14.76 on the 0-100 standardised scale. The median value
was 77.08. The minimum recorded score was 17.36 and
the maximum was 100. Individual item response distri-
bution covered all proposed response categories for all
items, although no individual simultaneously selected
the minimum score for all items in the scale. With the
exception of the undesirable side effects subscale, the
distribution of responses showed a slight negative skew-
ness; the item with the most skewed distribution (will-
ingness to continue treatment)i n c l u d e d4 4 %o ft h e
responses in the upper part of the scale. All distribu-
tions were unimodal. The undesirable side effects sub-
scale accumulated responses in the lower portion of the
scale; between 66% and 75% of the responses were
located in the category “No, not at all”.
The SATMED-Q total and ?domain scores signifi-
cantly correlated with the total and domain scores on
the Spanish version of the TSQM (Table 2). A correla-
tion of 0.74 was obtained between the composite scores
for both scales, with correlations ranging from 0.58 to
0.68 between dimensions having similar contents (p <
0.001 in all cases). A significant relationship (p < 0.01)
was also found between the scores on the SATMED-Q
and item #14 of the TSQM, ranging from 0.18 to 0.58.
The correlation between the medical care domain of the
SATMED-Q and item #14 of the TSQM, although sta-
tistically significant, was weak (r = 0.18). However, the
other domains showed moderate-to-good correlation
coefficients, supporting the validity of this item as an
anchor for calculating MID for the SATMED-Q tool.
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ences in satisfaction, statistically significant SATMED-Q
mean differences were observed at each level of differ-
ence in satisfaction (minimum, medium and large) as
compared with the reference (neutral) category (see
Table 3), meaning that the classification of different
levels of patient satisfaction by means of TSQM item
#14 is valid and appropriate for estimating the MID
with such item as an anchor-based method, as has pre-
viously been applied by others [25]. Observed difference
sizes versus the reference category were monotonous
and almost linear for the SATMED-Q total score and
Table 2 Pearson correlation coefficients between SATMED-Q domains, TSQM domains and TSQM item #14
TSQM
SATMED-Q Effectiveness Side effects Convenience of use General satisfaction Total score Item #14
Treatment effectiveness 0.68 0.19 0.32 0.67 0.61 0.55
Convenience of use 0.32 0.34 0.68 0.37 0.56 0.34
Impact on daily living/activities 0.44 0.19 0.28 0.55 0.50 0.45
Medical care 0.19 0.02NS 0.10** 0.28 0.19 0.18
Undesirable side effects 0.18 0.58 0.24 0.25 0.43 0.23
General satisfaction 0.60 0.27 0.41 0.68 0.66 0.58
Overall composite score 0.61 0.39 0.51 0.70 0.74 0.58
p < 0.001 in all cases, except: ** p < 0.01 and NS = Non-significant. TSQM = Treatment Satisfaction Questionnaire for Medications. SATMED-Q = Satisfaction with
Medicines Questionnaire.
Table 3 Standardised scores for SATMED-Q domains and total score by magnitude of difference in response categories
of TSQM item #14
Domain Difference N Mean SD F (p value)
Large 39 89.5 12.9 58.1 (p < 0.001)
Treatment effectiveness Moderate 136 80.1 18.2
Small 213 67.1 19.9
Reference 68 51.5 20.8
Large 39 90.4 15.1 26.3 (p < 0.001)
Convenience of use Moderate 136 81.3 20.8
Small 213 72.9 21.1
Reference 68 57.8 26.3
Large 39 81.8 18.9 40.4 (p < 0.001)
Impact on daily Moderate 136 74.1 22.2
living/activities Small 213 64.1 22.3
Reference 68 43.5 21.2
Large 39 85.9 21.5 10.7 (p < 0.001)
Medical care Moderate 136 81.1 18.7
Small 213 80.1 17.8
Reference 68 69.9 22.3
Large 39 94.5 9.7 60.4 (p < 0.001)
General satisfaction Moderate 136 86.5 17.4
Small 213 75.2 19.0
Reference 68 57.1 22.2
Large 39 92.9 15.2 12.2 (p < 0.001)
Undesirable Moderate 136 94.4 13.8
side effects Small 213 88.0 20.8
Reference 68 76.5 24.4
Large 39 89.3 8.7 88.8 (p < 0.001)
Composite score Moderate 136 82.5 11.3
Small 213 72.7 13.0
Reference 68 59.3 12.1
Values are means and SD (standard deviation). TSQM = Treatment Satisfaction Questionnaire for Medications. SATMED-Q = Satisfaction with Medicines
Questionnaire.
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side effects dimension, where a small decrease in the
size of differences versus the reference category was
observed for the large difference level (Figure 1), which
c o u l db ed u et ot h es m a l ls a m p l es i z ei nt h i sg r o u p( 3 9
subjects with only four responding extremely
dissatisfied).
Mean SATMED-Q scores (total and domain) in the
TSQM item #14 neutral satisfaction category and in the
satisfied/dissatisfied category are shown in Table 4. The
raw difference between the two mean scores represents
the estimated MID. MID estimates ranged from 10.3
(satisfaction with medical care domain) to 20.6 (satisfac-
tion with impact of medicines on daily living activities).
SEM values ranged from 5.9 (total score and satisfaction
with undesirable side effects) to 9.5 points (satisfaction
with treatment effectiveness). The magnitude of effect
size estimates was moderate to large, ranging from 0.58
(satisfaction with undesirable side effects) to 0.91 (over-
all satisfaction score). In particular, the effect size esti-
mate for the total score was the largest (0.91), indicating
that the estimated MID for the total score (13.4) seems
to be a reasonable magnitude for the minimum per-
ceived change in overall satisfaction with drug
treatment.
Table 5 contains bootstrap estimates for MID for each
dimension and total scores for the SATMED-Q. Boot-
strap mean values for 1000 samples were close to the
asymptotic theory estimates, with the exception of the
satisfaction with medical care dimension. Mean MID for
this dimension was close to 0 and the 95% confidence
interval included the null difference value, ranging from
negative to positive values. However, the difference for
the contiguous level of satisfaction (medium difference)
did detect positive differences (mean MID = 10.13, SE =
3.13).
When comparing effectiveness groups as assessed by
the clinician, differences in mean values for the
SATMED-Q dimension corresponding to satisfaction
with treatment effectiveness attained significance. Tak-
ing the Acceptable Effectiveness group as the reference,
the difference with the Poor Effectiveness group was the
largest (d = -23.4, SE = 5.78, p < 0.001), differences with
Good Effectiveness did not attain significance (d = 6.26,
SE = 2.54, p = 0.066), and the difference with Excellent
Effectiveness was also large (d = 18.76, SE = 2.76, p <
0.001).
Discussion
It is increasingly recognised that the patient viewpoint
should be taken into account when evaluating a medical
treatment. One domain of such a patient-oriented eva-
luation is patient satisfaction with treatment or treat-
ment satisfaction. Treatment satisfaction is a
documented area of interest within health outcomes
research and appears to be increasingly used as a
patient-reported outcome when testing new or existing
treatments [30]. Patient satisfaction with the medication
received is of growing concern in clinical practice. On
the one hand, this is because satisfaction helps evaluate
the benefits and convenience of the medication pro-
vided. On the other hand, the fact that treatment satis-
faction is associated with increased patient adherence to
therapy and to a greater patient desire to continue using
the drug may help predict treatment compliance and
improve effectiveness of the administered therapy [31,32],
with closer follow-up of those patients expected to
adhere less to treatment. The aim of this study was to
determine the minimally important difference (MID) for
the recently available SATMED-Q, an instrument for
exploring patient satisfaction with treatment for a medi-
cine on a generic basis.
T h eM I Df o u n di nt h i ss t u d ys h o w st h a tac h a n g e
within the range of 10.26-17.10 points in the total score
(on a scale of 0-100 points) would be required for a
change to be detectable by the patient in his/her level of
satisfaction with drug treatment, i.e. for a modification
in the treatment to be meaningful from the patient’s
perspective. Moreover, this noticeable change should
therefore be clinically meaningful for physicians in order
to help them take the appropriate health decision, such
as whether to continue the therapy or change it,
depending on the patient response. The MID for the
questionnaire domains ranged from 10.3 to 20.6. These
values could be considered relevant as they showed a
moderate-to-large effect size [27], meaning that patients
should be able to detect a change in drug treatment
when this actually happens.
However, the MID values detected were approximately
equivalent to 1.96 times the value of the corresponding
Figure 1 Mean SATMED-Q differences by TSQM item #14
difference level with respect to reference category and by
dimension.
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been interpreted previously as equivalent by other
authors also using this distribution-based
method [25,26,33-35]. The explanation for this discre-
pancy could be that, compared with other instruments
assessing quality of life, patient preference, etc., satisfac-
tion with medicinal treatment needs a larger difference
in scores to be detectable by the patient. Due to the
subjacent or latent construct of satisfaction, this could
even be expected. For example, during the development
of the PASAPQ questionnaire [25], Kozma et al. also
found a similar discrepancy in MID estimation between
anchor-based and distribution-based methods. In that
instrument, MID calculated with an anchor method was
between two and three times the value calculated with
distribution methods. However, when Vernon et al. [26]
developed the MSQ in patients with schizophrenia, they
found more congruence in MID estimation using both
anchor and distribution-based methods. Part of this lack
of congruence could be due to the fact that MSQ is a
one-item instrument in comparison with multi-item
questionnaires such as the PASAPQ or SATMED-Q.
Also, discrepancies could be due to the type of medical
interventions explored with such instruments or the
ceiling effect that these patient satisfaction instruments
may have by the very nature of this construct or by the
response categories used for the items [5]. Interestingly,
further research should clarify whether current methods
remain useful for triangulating the estimation of the
MID value of a PRO instrument or whether researchers
would need new approaches, particularly in the field of
patient satisfaction. In fact, we could not apply an
anchor-based method other than the one used here
mainly because this study was cross-sectional and there
was only one visit (i.e. a scale measuring change in
patient satisfaction could not be administered).
Two methodological issues should be taken into
account. Firstly, each dimension consists of 3 items on a
5-point Likert-type scale (except satisfaction with medi-
cal care, which contains only 2 items). Hence, raw
dimension scores will range from 0 to 20 and a 1-point
change will translate to less than 7 points on the 0-100
standardised scale, and a change of 10 points for the
satisfaction with medical care dimension. This being so,
a change of 10 to 20 points will be quite easy to accom-
plish from the moment when patient scores vary. On
Table 4 Minimally Important Difference (MID), standard error of measurement (SEM) and effect size of the
standardised SATMED-Q total and domain scores calculated for the sample of 456 patients to test psychometric
properties of the instrument
Distribution-
based MID
SATMED-Q
domain
SATMED-Q mean score at neutral
satisfaction category of TSQM item
#14
SATMED-Q mean score at satisfied/
dissatisfied category of TSQM item
#14
Anchor-
based
MID
1
SEM
2 One-
half
SD
Effect
size
3
Treatment
effectiveness
51.5 (20.8) 67.1 (19.9) 15.6 9.5 10.9 0.71
Convenience of
use
57.8 (26.3) 72.9 (21.1) 15.1 8.6 11.6 0.65
Impact on daily
living/activities
43.5 (21.3) 64.1 (22.3) 20.6 9.4 12.2 0,85
Medical care 69.9 (22.3) 80.1 (17.8) 10.3 8.1 11.9 0.43
General
satisfaction
57.1 (22.2) 75.2 (19.0) 18.2 8.1 10.6 0.83
Undesirable
side effects
76.5 (24.4) 88.0 (20.8) 11.5 5.9 10.0 0.58
Total score 59.3 (12.1) 72.7 (13.0) 13.4 5.9 7.4 0.91
Values are means (standard deviation). 1Computed as the raw difference between scores in neutral response and satisfied/dissatisfied categories of TSQM item
#14 used as an anchor reference. 2 SEM = Standard error of measurement obtained by multiplying the standard deviation of each domain or the total score in
the entire sample by the root square of 1 minus the coefficient of reliability (-Cronbach’s a). 3Obtained by dividing the MID of the domain or total score by the
standard deviation of the whole sample for that domain or total score. TSQM = Treatment Satisfaction Questionnaire for Medications. SATMED-Q = Satisfaction
with Medicines Questionnaire. SD = standard deviation.
Table 5 Bootstrap MID estimates for 1000 samples
SATMED-Q domain Mean
MID
SE 2.5
Percentile
97.5
Percentile
Treatment effectiveness 16.02 2.84 10.54 21.46
Convenience of use 15.29 3.51 8.15 22.04
Impact on daily living/
activities
21.07 2.98 14.99 26.91
Medical care -0.21 3.31 -6.68 6.47
General satisfaction 18.84 2.94 13.00 24.33
Undesirable side effects 11.44 3.41 4.66 18.30
Overall score 13.64 1.72 10.26 17.10
SATMED-Q = Satisfaction with Medicines Questionnaire. MID = Minimum
Important Difference. SE = standard error.
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tively skewed, and deviations from the main bulk of
scores usually reflect a large change.
As we have seen, results are less conclusive for the
satisfaction with medical care dimension. Differences
between adjacent satisfaction groups are difficult to dis-
tinguish according to bootstrap estimates and larger
changes need to be made in order for a patient to
recognise a meaningful change.
We find that variations greater than 6 points are
needed in order to consider a change in patient health
situation to be valid, at least as regards the satisfaction
with treatment effectiveness dimension. Nevertheless,
we cannot rule out other reasons explaining the range
of MID values obtained, such as the methods used here
to calculate the MID, which could be taken as a limita-
tion of this research. We were not able to use the typi-
cal prospective approach of measuring a change with an
external scale as the anchor for MID calculation in qual-
ity-of-life instruments, e,g, the Juniper et al. patient glo-
bal assessment scale [36-38]. Instead we used the ability
of the instrument to distinguish between the two nearest
levels of satisfaction, starting with a neutral category
where the subjects are unable to determine their level of
satisfaction. Another possible limitation is the calcula-
tion of the sample size, which was established in the ori-
ginal research by testing the psychometric properties of
the SATMED-Q, and not calculated for the MID.
Possible implications of the MID value of SATMED-
Q, from a clinical standpoint, still need to be estab-
lished. However, as mentioned previously, it may be
clinically meaningful for physicians in order to help
them take the appropriate health decision in the thera-
peutic management of patients. Other implications of
MID could be the use of this value to classify patient
responders/non-responders to treatment with medicines
or also for sample size calculation in clinical and/or
observational trials. For future prospects, this MID value
should be tested to explore its ability to correlate with
effectiveness of therapy and patient compliance with
treatment, since this could not be explored due to the
design of our study.
Conclusion
Taking into account the above limitations, the
SATMED-Q was demonstrated to be responsive to dif-
ferent levels of patient satisfaction with therapy in
chronically ill subjects. MID values for the instrument
are now available, allowing researchers to use it to
determine sample sizes for studies based on patient
satisfaction outcomes and/or as a measurement of effec-
tiveness in studies with end-points based on patient
perspectives.
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